Answers are grounded in this paper and cite their sources.
Although several biomarkers exist for patients with heart failure (HF), their use in routine clinical practice is often constrained by high costs and limited availability.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: